ArticleCurrent oncology (Toronto, Ont.)2026
Comparative Efficacy and Safety of First-Line Immune Checkpoint Inhibitors Plus Chemotherapy with or Without Bevacizumab in Advanced Non-Squamous Non-Small Cell Lung Carcinoma.
Ping Chen et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.